1-[5-(Hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-[5-(Hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
• 化学式: C₁₀H₁₁F₃N₂O₄
• 分子量: 280.2
• InChiKey: IPPUXBJGDIHFQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] PHARMACEUTICAL COMBINATION OF NINTEDANIB, TRIFLURIDINE AND TIPIRACIL FOR TREATING COLORECTAL CANCER<br/>[FR] COMBINAISON PHARMACEUTIQUE DE NINTÉDANIB, DE TRIFLURIDINE ET DE TIPIRACIL POUR LE TRAITEMENT DU CANCER COLORECTAL
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2017178428A1

  公开（公告）日：2017-10-19

  The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, especially metastatic colorectal cancer comprising 3-Z-[1-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)- N-methyl-amino)-anilino)- 1 -phenyl-methylene] -6-methoxycarbonyl-2-indo lino ne or a pharmaceutically acceptable salt thereof, and 2'-deoxy-5-(trifluoromethyl)uridine or a pharmaceutically acceptable salt thereof, and 5-chloro-6-[(2-iminopyrrolidin-l- yl)methyl]pyrimidine-2,4(lH,3H)-dione or a pharmaceutically acceptable salt thereof, wherein the molar ratio of 2'-deoxy-5-(trifluoromethyl)uridine or a pharmaceutically acceptable salt thereof, and 5-chloro-6-[(2-iminopyrrolidin-l-yl)methyl]pyrimidine- 2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, is 1 :0.5
• [EN] CONTROLLED RELEASE DRUG DIMERS<br/>[FR] DIMÈRES DE MÉDICAMENTS À LIBÉRATION CONTRÔLÉE
  申请人：RIPPLE THERAPEUTICS CORP

  公开号：WO2021024041A1

  公开（公告）日：2021-02-11

  The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.